Amedisys, Inc. AMED
Set alert
100.99 0.00 0.00%
At close · Aug 14
100.93 Day range 101.02
82.15 52-week range 101.02
- YTD
- +11.23%
- 1 year
- +3.24%
- Open
- 101.00
- Prev close
- 100.99
- Mkt cap
- 3.32B
- Vol
- 1.04M
- Avg vol
- 549.55K
- EPS
- 2.57
- P/E
- 39.30
- Div yield
- 0.00%
More statistics
- Low
- 100.93
- High
- 101.02
- Forward P/E
- 19.76
- Beta
- 0.90
- Short ratio
- 6.84
- Inst. own
- 96.37%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Jul 29, 2025
- 50-d avg
- 98.01
- 200-d avg
- 93.25
- 1y target
- 0.00
5Y chart
Events in this range
- Apr 24, 2024Earnings: —; estimate 1.01; surprise —%
- Jul 1, 2024Downgrade: William Blair · Outperform → Market Perform
- Jul 24, 2024Earnings: —; estimate 1.22; surprise —%
- Jul 25, 2024Rating: Cantor Fitzgerald · Neutral → Neutral
- Jul 31, 2024Downgrade: Deutsche Bank · Buy → Hold
- Nov 6, 2024Earnings: —; estimate 1.14; surprise —%
- Feb 12, 2025Rating: Stephens & Co. · Equal-Weight → Equal-Weight
- Feb 26, 2025Earnings: —; estimate 1.05; surprise —%
- Mar 4, 2025Rating: Stephens & Co. · Equal-Weight → Equal-Weight
- Apr 16, 2025Rating: RBC Capital · Outperform → Outperform
- Apr 23, 2025Earnings: —; estimate 1.13; surprise —%
- Jul 29, 2025Earnings: —; estimate 1.39; surprise —%
Signals (55)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Jun 2, 2025 | 1 year ago |
| SMA: Bearish | May 23, 2025 | 1 year ago |
| SMA: Bullish | Apr 25, 2025 | 1 year ago |
| SMA: Bullish | Apr 25, 2025 | 1 year ago |
| SMA: Bearish | Apr 10, 2025 | 1 year ago |
| SMA: Bearish | Apr 10, 2025 | 1 year ago |
| SMA: Bullish | Mar 27, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 23, 2025 | 1 year ago |
| SMA: Bullish | Dec 31, 2024 | 1 year ago |
| RSI: Oversold | Dec 3, 2024 | 1 year ago |
| SMA: Bearish | Nov 12, 2024 | 1 year ago |
| SMA: Bearish | Oct 28, 2024 | 2 years ago |
| SMA: Bullish | Oct 21, 2024 | 2 years ago |
| MACD: Sell Signal | Sep 23, 2024 | 2 years ago |
| SMA: Bearish | Sep 9, 2024 | 2 years ago |
| SMA: Bullish | Jul 1, 2024 | 2 years ago |
| SMA: Bullish | Jul 1, 2024 | 2 years ago |
| MACD: Buy Signal | Jul 1, 2024 | 2 years ago |
| MACD: Sell Signal | Jun 10, 2024 | 2 years ago |
| SMA: Bearish | Jun 3, 2024 | 2 years ago |
| SMA: Bearish | Jun 3, 2024 | 2 years ago |
| MACD: Buy Signal | May 17, 2024 | 2 years ago |
| SMA: Bullish | May 10, 2024 | 2 years ago |
| SMA: Bullish | May 10, 2024 | 2 years ago |
| SMA: Bearish | Feb 29, 2024 | 2 years ago |
| SMA: Bearish | Feb 29, 2024 | 2 years ago |
| SMA: Bullish | Feb 22, 2024 | 2 years ago |
| SMA: Bearish | Jan 25, 2024 | 2 years ago |
| SMA: Bullish | Jan 18, 2024 | 2 years ago |
| SMA: Bearish | Jan 11, 2024 | 2 years ago |
| MACD: Sell Signal | Jan 4, 2024 | 2 years ago |
| MACD: Buy Signal | Dec 21, 2023 | 2 years ago |
| SMA: Bullish | Nov 15, 2023 | 2 years ago |
| MACD: Sell Signal | Oct 31, 2023 | 3 years ago |
| SMA: Bearish | Oct 10, 2023 | 3 years ago |
| SMA: Bullish | Jun 6, 2023 | 3 years ago |
| SMA: Bullish | Jun 6, 2023 | 3 years ago |
| SMA: Bearish | May 30, 2023 | 3 years ago |
| SMA: Bullish | May 23, 2023 | 3 years ago |
| MACD: Buy Signal | Apr 11, 2023 | 3 years ago |
| MACD: Sell Signal | Mar 28, 2023 | 3 years ago |
| SMA: Bearish | Mar 7, 2023 | 3 years ago |
| SMA: Bullish | Jan 17, 2023 | 3 years ago |
| MACD: Buy Signal | Jan 10, 2023 | 3 years ago |
| RSI: Oversold | Nov 8, 2022 | 3 years ago |
| MACD: Sell Signal | Oct 3, 2022 | 4 years ago |
| SMA: Bearish | Sep 19, 2022 | 4 years ago |
| SMA: Bullish | Sep 12, 2022 | 4 years ago |
| SMA: Bearish | Aug 29, 2022 | 4 years ago |
| MACD: Buy Signal | Jul 25, 2022 | 4 years ago |
| SMA: Bullish | Jul 11, 2022 | 4 years ago |
| SMA: Bearish | Apr 18, 2022 | 4 years ago |
| SMA: Bullish | Mar 21, 2022 | 4 years ago |
| SMA: Bearish | Mar 14, 2022 | 4 years ago |
| SMA: Bullish | Feb 28, 2022 | 4 years ago |
Key statistics
- Market cap
- 3.32B
- Enterprise value
- 3.48B
- Trailing P/E
- 39.30
- Forward P/E
- 19.76
- PEG ratio
- 0.00
- Price / sales
- 1.38
- Price / book
- 2.69
- EPS (TTM)
- 2.57
- Beta
- 0.90
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 3.56%
- Revenue (TTM)
- 2.40B
- Revenue growth
- 5.20%
- Free cash flow
- 300.69M
- Total cash
- 337.30M
- Total debt
- 450.51M
- Return on equity
- 6.67%
- Shares outstanding
- 32.89M
- Short % of float
- 9.90%
- 50-day average
- 98.01
- 200-day average
- 93.25
Analyst view
Consensus: hold
Hold
Price target (mean) 0.00
Ratings (0m) 6 1 buy · 4 hold · 1 sell
- Strong buy1
- Buy0
- Hold4
- Sell1
- Strong sell0
Next earnings
Jul 29, 2025
Expected Jul 29, 2025. Consensus EPS estimate 1.20.
Financials — quick view
AMED Revenue — quarterly 621.86M
AMED Net income — quarterly 28.08M
AMED EPS — quarterly 0.85
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jul 29, 2025 | Jun 1, 2025 | 1.39 | — | — | — |
| Apr 23, 2025 | Mar 1, 2025 | 1.13 | — | — | — |
| Feb 26, 2025 | Dec 1, 2024 | 1.05 | — | — | — |
| Nov 6, 2024 | Sep 1, 2024 | 1.14 | — | — | — |
| Jul 24, 2024 | Jun 1, 2024 | 1.22 | — | — | — |
| Apr 24, 2024 | Mar 1, 2024 | 1.01 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 16, 2025 | RBC Capital | reit | Outperform | Outperform |
| Mar 4, 2025 | Stephens & Co. | reit | Equal-Weight | Equal-Weight |
| Feb 12, 2025 | Stephens & Co. | reit | Equal-Weight | Equal-Weight |
| Jul 31, 2024 | Deutsche Bank | down | Buy | Hold |
| Jul 25, 2024 | Cantor Fitzgerald | reit | Neutral | Neutral |
| Jul 1, 2024 | William Blair | down | Outperform | Market Perform |
About Amedisys, Inc.
Amedisys, Inc. provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment provides a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care, and palliative care to patients in their homes. Amedisys, Inc. was formerly known as Analytical Nursing Management Corp. and changed its name to Amedisys, Inc. in August 1995. The company was founded in 1982 and is headquartered in Baton Rouge, Louisiana with an additional office in Nashville, Tennessee. As of August 14, 2025, Amedisys, Inc. operates as a subsidiary of Optum, Inc.
- Sector
- Healthcare
- Industry
- Medical Care Facilities
- Country
- United States
- Website
- amedisys.com
News
- Joel Greenblatt's Strategic Moves: A Closer Look at SPDR S&P 500 ETF Trust
- Twilio Set to Join S&P MidCap 400
- Amedisys: Thoughts On UnitedHealth Merger, Plus Underlying Factors
- Amedisys (AMED) is a Top-Ranked Value Stock: Should You Buy?
- Amedisys (AMED) Q2 Revenue Tops 5%
- Here's What Key Metrics Tell Us About Amedisys (AMED) Q2 Earnings
- Amedisys (AMED) Beats Q2 Earnings and Revenue Estimates
- Amedisys Reports Second Quarter 2025 Financial Results
- Here's Why You Should Retain AMED Stock in Your Portfolio for Now
- AMED or CHE: Which Is the Better Value Stock Right Now?
Your note
Sign in to keep a note on AMED — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ASHWORTH RICHARD M | Chief Executive Officer | Conversion of Exercise of derivative security | Aug 13, 2025 | 0 |
| BOHNERT DENISE M. | Officer | Conversion of Exercise of derivative security | Aug 13, 2025 | 0 |
| CAPPS VICKIE LYNN | Director | Stock Award(Grant) | May 1, 2025 | 9,818 |
| COYE MOLLY JOEL | Director | Stock Award(Grant) | May 1, 2025 | 8,818 |
| GINN SCOTT G | Chief Financial Officer | Conversion of Exercise of derivative security | Aug 13, 2025 | 0 |
| GUIDROZ ALLYSON | Officer | Stock Award(Grant) | Aug 5, 2025 | 9,473 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 10.17% | 3,345,633 | 337.88M | Jun 29, 2025 |
| Vanguard Group Inc | 9.25% | 3,041,392 | 307.15M | Jun 29, 2025 |
| Pentwater Capital Management Lp | 5.22% | 1,715,084 | 173.21M | Jun 29, 2025 |
| FIL LTD | 3.99% | 1,312,785 | 132.58M | Jun 29, 2025 |
| Alpine Associates Management Inc. | 3.34% | 1,096,920 | 110.78M | Jun 29, 2025 |
| State Street Corporation | 3.25% | 1,067,613 | 107.82M | Jun 29, 2025 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Mid-Cap ETF | 3.25% | 1,067,364 | 107.79M | Jun 29, 2025 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.14% | 1,032,785 | 104.30M | Mar 30, 2025 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.49% | 818,018 | 82.61M | Mar 30, 2025 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Value Index Fund | 1.61% | 529,664 | 53.49M | Mar 30, 2025 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.53% | 504,318 | 50.93M | Mar 30, 2025 |
| CALAMOS INVESTMENT TRUST/IL-Calamos Market Neutral Income Fund | 1.50% | 492,439 | 49.73M | Apr 29, 2025 |